LAS VEGAS, August 20, 2025--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company"), today announced the closing of its previously announced $7 million financing. As of ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a ...

PharmaCyte Biotech is watched today as Biotech event timing during a healthcare-led week. Penny Stocks names remain shaped by rates, energy moves and shifting demand. Verified market context favors a ...

PharmaCyte Biotech Inc. (NASDAQ:PMCB) shares skyrocketed 67.8% on Tuesday after the company announced it had completed the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), ...

(RTTNews) - PharmaCyte Biotech, Inc. (PMCB) has made a $5 million investment in Femasys, Inc. (FEMY), a biomedical company. Femasys offers a broad portfolio of in-office, accessible solutions, ...

PharmaCyte Biotech Q1 EPS $(0.54) Up From $(1.23) YoY, Sales $0.00, Same YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(0.54) per share. This is a 56.1 percent increase over ...

PharmaCyte Biotech (PMCB) last issued guidance on July 11, 2022 for fiscal year 2022. The company guided earnings per share in the range of $-0.27 - $-0.27, compared to a consensus EPS estimate of $-0 ...